Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo. Based on these interim results, the data and safety monitoring board overseeing the trial recommended that the primary results of the study be released.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
